Jeff Metz | Horse Racing Free Tips

Bisphosphonate Complaint Against Metz Dismissed

A complaint against trainer Jeff Metz regarding a positive bisphosphonate test from last year was dismissed during a closed session vote of the California Horse Racing Board commissioners Sept. 15. According to a release from the CHRB, the board believed it would be unfair to punish Metz for the positive test of his trainee, Camino de Estrella, because testing and a subsequent investigation revealed that the substance had been administered in 2018–well before the horse was in Metz's care. The Maddy Laboratory at UC Davis detected the presence of Tiludronic Acid in a urine sample taken from Camino de Estrella after he finished sixth in a race at Santa Anita last Sept. 27. The horse was subsequently disqualified and will remain so.

The post Bisphosphonate Complaint Against Metz Dismissed appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

CHRB Dismisses Bisphosphonate Complaint Against Jeff Metz

California Horse Racing Board commissioners (Board) voted during closed session Sept. 15 to dismiss a complaint against trainer Jeff Metz pertaining to a positive test last year for a bisphosphonate in one of the horses in his care, Camino de Estrella.

The Board believed it would be unfair to punish Metz when both testing and investigation revealed that the bisphosphonate administration occurred in 2018, well before Metz ever trained the horse.

The complaint (posted on the CHRB website since December) stated that the Maddy Laboratory at UC Davis detected Tiludronic Acid (Tildren, a bisphosphonate) in the urine sample taken from Camino de Estrella after he finished sixth in the third race at Santa Anita on Sept. 27, 2020. The presence of the Class 1 drug prompted the stewards at Del Mar to later disqualify Camino de Estrella and order the redistribution of the purse. The disqualification remains in force and is not affected by the dismissal of the complaint against Metz.

The Board dismissed the complaint pursuant to Business & Professions Code 19577 (d): “Any recommendation to the board by the executive director to dismiss the matter shall be by mutual agreement with the equine medical director. The authority for the disposition of the matter shall be the responsibility of the board.”

The post CHRB Dismisses Bisphosphonate Complaint Against Jeff Metz appeared first on Horse Racing News | Paulick Report.

Source of original post

California Horse Racing Board Issues Bisphosphonate Complaint Against Jeff Metz

The California Horse Racing Board issued a complaint against trainer Jeff Metz last week over a finding of bisphosphonates in the Sept. 27, 2020 post-race sample of the gelding Camino De Estrella, reports the Daily Racing Form. The drugs are not yet specifically classified in California, so the positive is being adjudicated under the “prohibited substances” rule with a Class 1, Category A penalty.

However, Metz's attorney Darrell Vienna believes the trainer will be exonerated. Popular at the claim box, Camino de Estrella has been in the care of five different trainers since 2019, including Tim Yakteen, Mark Glatt, Steve Knapp, Metz, and most recently Bill Spawr.

“There is a record of a veterinarian administering the drug when he was not in Mr. Metz's care, in 2019,” Vienna told DRF. “I can say with certainty that Jeff never administered bisphosphonates to that horse. We're confident that the truth will come out, because we think the CHRB already knows the truth.”

Bisphosphonates were approved for equine use in the United States approximately six years ago, to treat horses with symptoms of navicular syndrome, a common, nagging foot pain in older horses. Before the drugs were approved for horses in the U.S., they were used in Europe and veterinarians could legally import them to treat American horses. Having them available to American practitioners who perhaps couldn't previously afford the import process has made a world of difference to mature horses dealing with navicular syndrome – and there are a lot of them. Roughly a third of chronic front leg lamenesses are believed to be related to navicular pain. Generally, bisphosphonates have been safe and effective in the population they're intended for.

Bisphosphonates (sold commercially as Osphos and Tildren) are FDA-approved in horses four years old and up, and are not approved for use in mares who are pregnant or lactating. The reason for those restrictions is unanswered questions about potential side effects. Bisphosphonates do their work by reducing the action of cells called osteoclasts, which clear away damaged bone and make way for osteoblasts to lay down new bone. In a young equine skeleton, this could disrupt the growth cycle.

The CHRB did prohibit the administration of bisphosphonates beginning July 1, 2020, via rule 1867.1, which also prohibits any horse from entering CHRB grounds that has been administered the drug within six months.

Since Camino de Estrella would have been five years old in 2019, administration of a bisphosphonate was legal at that time only if the gelding had a diagnosis of navicular disease.

Vienna argued that “the available science on bisphosphonates clearly demonstrates that the drug can be found more than 2 1/2 years after the drugs have been administered, due to their unique ability to lie dormant in bone but become 'active' in the horse's circulatory system when bone is in need of repair.”

Bisphosphonate Complaint Issued Against Metz By CHRB

A complaint involving a banned bisphosphonate has been lodged by the California Horse Racing Board (CHRB) against trainer Jeffrey Metz, summoning him to a stewards' hearing.

According to a CHRB complaint dated Apr. 29, a positive for tiludronic acid was confirmed via split-sample testing from Camino de Estrella (Mineshaft), who finished sixth in the third race Sept. 27, 2020, at Santa Anita.

The now-7-year-old gelding was claimed that day for $20,000, and has finished no better than sixth in four subsequent starts for a four-way partnership that includes trainer Bill Spawr.

The complaint states that, “Tiludronic Acid is considered a prohibited drug substance Class 1 Penalty Category A,” which is the most severe classification.

However, tiludronic acid is not specifically listed as an individual substance on the CHRB's “Classification of Foreign Substances” list, which is modeled after the Uniform Classification Guidelines for Foreign Substances list published by the Association of Racing Commissioners International (ARCI).

But a separate CHRB rule states that, “Any drug or its metabolite or analogue thereof found to be present in an official test sample that is not classified in Rule 1843.2 of this division shall be classified as a Class 1 substance and a Category 'A' penalty until classified by the Board.”

On July 1, 2020, the CHRB enacted Rule 1867.1, which broadly prohibits the administration of bisphosphonates to any horse within a facility regulated by the CHRB and also prohibits any horse from entering the grounds if it has been administered a bisphosphonate within the prior six months (effectively making the rule retroactive to Jan. 1, 2020).

According to the ARCI's ruling database, Metz has two medication violations within the past five years, one each for Class 3 (xylazine in 2018, fined $250) and Class 4 (triamcinolone acetonide in 2016, fined $300). Both occurred at Emerald Downs, where he has won four training titles, and on both occasions the stewards there cited Metz's lack of a history of medication violations in issuing penalties for those two offenses.

In California, the recommended penalties for first-time Class 1 violations by a trainer call for a minimum one-year suspension and a minimum fine of $10,000, although mitigating circumstances can be taken into consideration.

The complaint states that “the horse shall be disqualified and any purse money forfeited.” The complaint lists the owners of Camino de Estrella at the time of the positive test as Jeffrey West (Saratoga West), Scott Gruender (Horseplayers Racing Club) and Jeremy Hodges.

No date for a stewards' hearing was listed on the complaint.

The post Bisphosphonate Complaint Issued Against Metz By CHRB appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post